Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-β-lactamase-producing Escherichia coli isolates

Journal of Clinical Microbiology

Volumn 45, Issue 8, 2007, Pages 2740-2742

  Sorlozano, Antonio ^a   Gutierrez, Jose ^a,c   Jimenez, Antonio ^b   Luna, Juan De Dios ^a   Martínez, José Luis ^b  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; EXTENDED SPECTRUM BETA LACTAMASE; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATION; CORRELATION COEFFICIENT; ESCHERICHIA COLI; GENE; GENE MUTATION; GENE STRUCTURE; GYRA GENE; GYRB GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARC GENE; PARE GENE; PRIORITY JOURNAL; QUINOLONE RESISTANCE DETERMINING REGION;

ANTI-BACTERIAL AGENTS; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MUTATION, MISSENSE;

ESCHERICHIA COLI;

EID: 34548075831     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01093-07     Document Type: Article

References (17)

1. Alos, J. I. 2003. Quinolones. Enferm. Infecc. Microbiol. Clin. 21:261-267.
2. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard. CLSI publication M7-A7. Clinical and Laboratory Standards Institute, Wayne, Pa.
3. Daza, R., J. Gutierrez, and G. Piedrota. 2001. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int. J. Antimicrob. Agents 18:211-215.
4. Everett, M. J., Y. F. Jin, V. Ricci, and L. J. Piddock. 1996. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob. Agents Chemother. 40:2380-2386.
5. Hernandez, J. R., A. Pascual, R. Canton, L. Martinez-Martinez, and Grupo de Estudio de Infeccion Hospitalaria. 2003. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals (GEIH-BLEE Project 2002). Enferm. Infecc. Microbiol. Clin. 21:77-82.
6. Hopkins, K. L., R. H. Davis, and E. J. Threlfall. 2005. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments. Int. J. Antimicrob. Agents 25:358-373.
7. Komp, L. P., A. Karlsson, and D. Hughes. 2003. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob. Agents Chemother. 47:3222-3232.
8. Lautenbach, E., B. L. Strom, W. B. Bilker, J. B. Patel, P. H. Edelstein, and N. O. Fishman. 2001. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae. Clin. Infect. Dis. 33:1288-1294.
9. Oteo, J., and J. Campos. 2004. Quinolone use and resistance. Enferm. Infecc. Microbiol. Clin. 22:201-203.
10. Poirel, L., J. D. Pitout, L. Calvo, J. M. Rodriguez-Martinez, D. Church, and P. Nordmann. 2006. In vivo selection of fluoroquinolone- resistant Escherichia coli isolates expressing plasmid-mediated quinolone resistance and expanded-spectrum β-lactamase. Antimicrob. Agents Chemother. 50:1525-1527.
11. Queipo-Zaragoza, J. A., A. Budía-Alba, M. J. Mascaros-Garcia, A. Gomez-Ferrer, M. Gobernado, and J. F. Jimenez-Cruz. 2000. Evolución de la resistencia microbiana a fluorquinolonas en un hospital terciario. Actas Urol. Esp. 24:381-387.
12. Ruiz, J., S. Casellas, M. T. Jimenez de Anta, and J. Vila. 1997. The region of the parE gene, homologous to the quinoione-resistant determining region of the gyrB gene, is not linked with the acquisition of quinolone resistance in Escherichia coli clinical isolates. Antimicrob. Chemother. 39:839-840.
13. Sorlozano, A., J. Gutierrez, F. Fernandez, M. J. Soto, and G. Piedrola. 2004. A preliminary study on the presence of extended-spectrum beta-lactamases (ESBL) in clinical isolates of Escherichia coli in Granada (Spain). Ann. Microbiol. 54:227-232.
14. Sorlozano, A., J. Gutierrez, J. D. Luna, J. Oteo, J. Liebana, M. J. Soto, and G. Piedrola. 23 March 2006, posting date. High presence of extended-spectrum β-lactamases and resistance to quinolones in clinical isolates of Escherichia coli. Microbiol. Res. doi:10.1016/j.micres.2006. 02.003. [Epub ahead of print.]
15. Sorlozano, A., J. Gutierrez, M. Palanca, M. J. Soto, and G. Piedrola. 2004. High incidence of extended-spectrum beta-lactamases among outpatient clinical isolates of Escherichia coli: a phenotypic assessment of NCCLS guidelines and a commercial method. Diagn. Microbiol. Infect. Dis. 50:131-134.
16. Vila, J., J. Ruiz, P. Goñi, and M. T. de Anta. 1996. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 40:491-493.
17. Vila, J., J. Ruiz, F. Marco, A. Barcelo, P. Goñi, E. Giralt, and T. Jimenez de Anta. 1994. Association between double mutation in gyrA gene of ciprofloxacin resistant clinical isolates of Escherichia coli and MICs. Antimicrob. Agents Chemother. 38:2477-2479.